医学大突破！埃博拉的治疗方法开始奏效

An experimental drug is helping patients infected with Ebola survive the virus as it sweeps across the Democratic Republic of Congo, where an outbreak has already killed at least 1,800 people.

一种实验性药物可以帮助感染埃博拉病毒的患者存活下来，埃博拉席卷刚果民主共和国，已有至少1,800人因此丧命。

strongly positive results with the treatment made by US drugmaker Regeneron Pharmaceuticals Inc., called REGN-EB3, led investigators to stop the trial just nine months after it began and change its design, dropping the previous standard of care and another experimental therapy.

美国制药公司再生元制药公司研制的治疗效果明显的REGN-EB3让研究者仅仅在9个月之后就停止了试验并改变了试验设计，放弃了以前的标准治疗药物和另一种实验性疗法。

Patients across the country will now get either REGN-EB3 or mAb114, a drug that's being developed by the US National Institute of Allergy and Infectious Diseases that also appeared promising.

全国的病人现在可以得到REGN-EB3或者mAb114，mAb114是国家过敏与感染性疾病研究院正在研制的一种药物，也很有效。

The medications may help reduce deaths and encourage those who are just starting to show signs of the disease to seek care. So far, two-thirds of the people infected in the latest outbreak have died. Violence in Congo has added to the difficulties in containing the epidemic.

这些药物有助于减少死亡人数并鼓励那些刚开始出现症状的人寻求治疗。截止目前，最近一次埃博拉疫情中三分之二染病患者已死亡，而且刚果的暴力冲突使流行病更难控制。

"We do have now what looks like treatments for a disease which not too long ago we really had no therapeutic approach at all," said Anthony Fauci, director of the institute.

该机构负责人Anthony Fauci说：“我们现在的确好像找到了疾病的疗法，而不久前我们还一点办法都没有。”

"We may be able to improve the survival of people with Ebola, and it may even make people more enthusiastic about coming to care."

“我们可能能够提高埃博拉患者的存活率了，甚至还能使人们更愿意前来治疗。”

The study compared experimental medicines with Mapp Biopharmaceutical Inc.'s ZMapp, which was considered the standard of care after a previous trial suggested it may help reduce death rates.

这项研究将实验性药物和马普生物制药公司的ZMapp药物进行了对比，ZMapp被认为是标准治疗药物，此前一项试验表明它可能有助于降低死亡率。